Back to Agenda
Major Reforms and Strengthened International Cooperation – What Is Happening in China?
Session Chair(s)
Carol Zhu, MBA
Vice President, Portfolio and Project Management
JW Therapeutics, China
The Chinese legal framework for medical products has undergone major reforms in the last years. The new pieces of legislation are now coming into force one by one. It is most relevant for companies to be abreast with the changes the new legislation brings for this important market. In addition, the China Food and Drug Administration has strengthened and enhanced its international cooperation. The underlying strategy as well as some recent developments will be outlined, such as the role and involvement of CFDA in ICH and ICMRA.
Speaker(s)
China Regulatory Reform in Review and Approval and Global Collaboration
Xiaoling Qin
China Food and Drug Adminsitration (CFDA), China
Deputy Director General, Department of International Cooperation
Xiangyu Wang
Xiangyu Wang
Division Director, Department of International Cooperation, China
New Approaches from China Regulatory Authority to Foster Innovation - Industry Perspective
Xiaojun (Wendy) Yan, MD, MBA
BeiGene (Beijing) Co., Ltd., China
Senior Vice President, Chief Regulatory Officer
Panel Discussion
Melly Lin
F. Hoffmann-La Roche Ltd, Switzerland
CMC Regulatory Policy Lead, Pharma Technical Regulatory
Panel Discussion
Jessica Liu, MD
Tigermed Consulting Co., Ltd, China
VP, Head of Merges and Acquisition Management Department
Have an account?